April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study Researchers have identified a distinct profile of self-reactive antibodies that appear in the blood years before the first clinical signs of multiple sclerosis (MS), which they believe could be used to help diagnose the neurodegenerative disease. The antibodies were found in about 10% of people who developed MS and…
April 23, 2024 News by Mary Chapman It’s year 10 for MSAA’s upcoming Improving Lives Benefit for MS With this year’s fundraiser, the Multiple Sclerosis Association of America (MSAA) is marking its 10th annual Improving Lives Benefit — an event that shines a light on uplifting members of the multiple sclerosis (MS) community and outstanding corporate partners. The affair will take place on May 15 at…
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus…
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of…